Physician profile
Gene Kim
NPI 1639332372
$16,922.84
in general payments reported to CMS, 2019-2025
23 companies · $1,051 in 2025
The $1,051 reported for 2025 was more than what 78% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,130 · 2020: $195 · 2021: $6,536 · 2022: $319 · 2023: $634 · 2024: $2,057 · 2025: $1,051.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,742.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec Cataract Technology INC. | $6,000.00 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $4,649.23 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $1,515.65 | 2019-2021 | |
| Alcon Vision LLC | $1,015.02 | 2019-2025 | Wavelight Ex500 Excimer Laser, Wavelight Refractive Suite, Contoura Vision |
| Bausch & Lomb Americas INC. | $640.68 | 2022-2024 | Xiidra, Vyzulta, Miebo |
| Rxsight INC | $561.46 | 2023-2025 | Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Glaukos Corporation | $321.55 | 2024-2025 | Idosetr, Istent Infinite, Ce-Marked Kxla System |
| Sun Pharmaceutical Industries INC. | $314.89 | 2019-2025 | Cequa |
| Sight Sciences, INC. | $298.64 | 2024-2025 | Omni Surgical System, Sion Surgical Instrument |
| Abbvie INC. | $289.79 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $264.47 | 2024-2025 | Xdemvy |
| Haag-Streit USA, INC. | $193.38 | 2024 | |
| Dompe US, INC. | $167.17 | 2019-2024 | Oxervate |
| New World Medical,INC. | $161.17 | 2019 | |
| Janssen Biotech, INC. | $125.00 | 2023 | Tremfya |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $118.23 | 2024 | Cystadrops |
| Carl Zeiss Meditec USA, INC. | $94.28 | 2023 | Visumax |
| Spark Therapeutics, INC. | $81.82 | 2019 | |
| Amgen INC. | $39.59 | 2025 | Tepezza |
| Biotissue Holdings INC. | $24.62 | 2025 | |
| Allergan, INC. | $16.60 | 2021 | |
| Harrow Eye, LLC | $14.88 | 2025 | Vevye |
| Novartis Pharmaceuticals Corporation | $14.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gene Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.